Human Microbiome Manufacturing Services Market
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The human microbiome manufacturing services market is projected to reach USD 0.27 billion by 2031 from USD 0.11 billion in 2025, at a CAGR of 16.7% from 2025 to 2031. The growth of the human microbiome manufacturing services market is driven by the accelerating development of live biotherapeutic products (LBPs), increasing outsourcing of GMP-compliant microbiome production, and strong investments in next-generation microbial therapeutics. Additionally, growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
KEY TAKEAWAYS
-
By RegionNorth America accounted for the largest share of the human microbiome manufacturing services market in 2024 due to the strong concentration of advanced CDMOs and robust biopharmaceutical activity.
-
By TypeBy type, the fermentation & downstream processing segment is expected to register the highest CAGR of 16.8% due to the central role of these processes in producing high-quality, scalable, and GMP-compliant live biotherapeutic products.
-
By DiseaseBy disease, the gastrointestinal disease segment accounted for the largest share of the human microbiome manufacturing services market in 2024 due to the concentration of clinical programs targeting gut-related conditions.
-
By End UserBy end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the human microbiome manufacturing services market in 2024, due to the extensive research and development (R&D) and commercialization of microbiome-based therapeutics.
-
Competitive LandscapeLonza, Evonik, and Eurofins Scientific were identified as some of the star players in the human microbiome manufacturing services market, given their strong market share and service footprint.
-
Competitive LandscapeCerbios-Pharma SA, List Biological Labs, Inc., and Elise Biopharma, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The human microbiome market is driven by the development of live biotherapeutic product (LBP) pipelines, rising outsourcing by pharmaceutical and biotechnology companies, and the increasing need for GMP-compliant microbial production. Additionally, service providers are collaborating with innovators to accelerate scale-up, ensure compliance with regulations, and help bring next-generation microbiome-based therapeutics to market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The human microbiome manufacturing services market is witnessing a shift from traditional, small-scale microbial fermentation and basic QC testing toward GMP-grade, large-scale production and automated, closed-system microbiome platforms. New revenue sources are driven by advanced manufacturing services for live biotherapeutic products, precision multi-strain formulations, and integrated CMC development. These trends enable clients, including pharmaceutical, academic, and clinical organizations, to adopt high-throughput, standardized, and automated workflows, resulting in faster development, improved product safety, higher reproducibility, and reduced operational costs.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing pipeline of live biotherapeutic products
-
Shift toward standardized, regulatory-compliant microbiome manufacturing
Level
-
Limited availability of GMP infrastructure and expertise
-
Variability and Instability of microbial strains
Level
-
Emergence of AI-driven and automated microbial manufacturing platforms
-
Expansion of personalized microbiome therapeutics and companion diagnostics
Level
-
Complex global regulatory landscape for live biotherapeutics
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing pipeline of live biotherapeutic products
The growing pipeline of live biotherapeutic products (LBPs) represents a significant driver for the human microbiome products market. As more and more LBP therapies transition from research into and through clinical trials, there will be an increasing need for reliable partners who can assist with strain development and production. Current LBP therapies are expanding into new indications within gastrointestinal, metabolic, immune, and infectious disease areas. As more therapies enter these phases, the need for expertise within these microbial production labs and facilities increases.
Restraint: Limited availability of GMP infrastructure and expertise
The market is constrained based on the limited availability of GMP-compliant facilities and technical expertise for live biotherapeutics. Producing living microbes requires rigorous environmental controls, special equipment, and specially trained staff. The scarcity of this infrastructure is limiting productive capacity and raising costs, creating challenges for small and mid-sized biotech companies looking to scale their microbiome-based therapies, from clinical development to commercial production.
Opportunity: Emergence of AI-driven and automated microbial manufacturing platforms
Advances in AI and automation are opening up new avenues for growth opportunities within microbiome production. AI-driven platforms have the capability to optimize microbial strain selection, fermentation methods, and quality control procedures, and automated manufacturing systems enhance scalability, traceability, and operational efficiency. These new technologies eliminate human error, accelerates time-to-market, decreases production costs, and attracts large numbers of pharmaceutical firms and new biotech enterprises that need to invest in next-generation live biotherapeutic production solutions.
Challenge: Complex global regulatory landscape for live biotherapeutics
A major challenge in human microbiome manufacturing is navigating the complex and evolving regulatory landscape. Live biotherapeutics are subjected to stringent guidelines across different regions, encompassing safety, potency, stability, and labelling requirements. Variability in approval pathways among the US, Europe, and the Asia Pacific complicates global commercialization strategies, necessitating robust regulatory expertise and compliance frameworks, which increase development timelines and operational costs for manufacturers in this nascent yet promising market.
Human Microbiome Manufacturing Services Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Microbiotica contracted Biose Industrie for GMP manufacturing of its multi-strain bacterial consortia candidates. The collaboration supports manufacturing for Microbiotica’s lead programs (e.g. for melanoma, ulcerative colitis) by scaling up anaerobic/aerobic bacterial fermentation, freeze-drying, and production of stable, capsule-based formulations for clinical trials | Enabled cGMP-compliant production of microbiome therapeutics | Scalable fermentation | Reduced lead time |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The human microbiome manufacturing services market ecosystem consists of service providers (Lonza, Novonesis, and Eurofins), regulatory bodies (European Medicines Agency, US Food & Drug Administration, UK Government), raw material suppliers (ProDigest, Novonesis, Lesaffre), and end users (NHS, Massachusetts Institute of Technology, Institut Pasteur). Raw material suppliers provide microbial strains, fermentation inputs, and specialized substrates, which are utilized by service providers to manufacture microbiome-based therapeutics, research tools, and other related products. Regulatory authorities establish approval protocols, safety standards, and clinical evaluation guidelines to ensure product quality and compliance. End users, including hospitals and research institutes, drive the adoption of advanced microbiome solutions for clinical care, research, and translational applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Human Microbiome Manufacturing Services Market, By Type
In 2024, fermentation & downstream processing dominated the human microbiome manufacturing services market. This dominance is attributed to its essential role in producing high-quality, GMP-compliant microbial products. Fermentation enables controlled, large-scale cultivation of diverse microbial strains, while downstream processing ensures purification, stabilization, and potency.
Human Microbiome Manufacturing Services, By Disease
In 2024, gastrointestinal diseases dominated the human microbiome manufacturing services market, driven by the high prevalence of gut-related disorders and the strong clinical focus on microbiome-based therapeutics for conditions such as IBD, IBS, and recurrent C. difficile infection.
Human Microbiome Manufacturing Services, By End User
In 2024, pharmaceutical & biotechnology companies dominated the human microbiome manufacturing services market, driven by their extensive involvement in developing live biotherapeutic products, microbiome-based drugs, and next-generation probiotics. These companies increasingly rely on specialized CDMOs for GMP-grade fermentation, anaerobic processing, and advanced analytical testing to accelerate clinical programs and reduce internal infrastructure costs.
REGION
North America to be fastest-growing region in global aerospace materials market during forecast period
Human Microbiome Manufacturing Services Market: COMPANY EVALUATION MATRIX
In the human microbiome manufacturing services market matrix, Lonza emerges as the star, driven by its advanced GMP-compliant microbial manufacturing platforms and strong clinical-stage live biotherapeutic programs. Lallemand Inc. is emerging as a leader, supported by its expanding contract manufacturing capabilities and growing focus on next-generation probiotics and live biotherapeutics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Lonza (Switzerland)
- Evonik (Germany)
- Lallemand Inc. (Canada)
- Cerbios-Pharma SA (Canada)
- List Biological Labs, Inc. (US)
- Elise Biopharma (US)
- Euofins Scientific (Luzembourg)
- Charles River Laboratories (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.09 Billion |
| Market Forecast in 2031 (Value) | USD 0.27 Billion |
| Growth Rate | CAGR of 16.7% from 2025-2031 |
| Years Considered | 2023-2031 |
| Base Year | 2024 |
| Forecast Period | 2025-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
WHAT IS IN IT FOR YOU: Human Microbiome Manufacturing Services Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown |
|
Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies across strain development and downstream processing for maximum regional impact |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- September 2024 : Lonza expanded its microbial manufacturing capacity in Germany, scaling up its ability to produce live biotherapeutic products (LBPs). This expansion enhances Lonza's ability to meet rising demand for clinical- and commercial-scale microbiome and biologics manufacturing.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
- 4.1 INTRODUCTION
-
4.2 MARKET DYNAMICSDRIVERSRESTRAINTSOPPORTUNITIESCHALLENGES
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
-
5.1 PORTER’S FIVE FORCES ANALYSISTHREAT OF NEW ENTRANTSTHREAT OF SUBSTITUTESBARGAINING POWER OF SUPPLIERSBARGAINING POWER OF BUYERSINTENSITY OF COMPETITION RIVALRY
-
5.2 MACROECONOMIC OUTLOOKINTRODUCTIONGDP TRENDS AND FORECASTTRENDS IN GLOBAL HEALTHCARE INDUSTRYTRENDS IN GLOBAL PHARMA INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 ECOSYSTEM ANALYSIS
-
5.5 PRICING ANALYSISINDICATIVE PRICING ANALYSIS OF HUMAN MICROBIOME MANUFACTURING SERVICES, BY END-USE INDUSTRY, 2024INDICATIVE PRICING ANALYSIS OF HUMAN MICROBIOME MANUFACTURING SERVICES, BY TYPE, 2024INDICATIVE PRICING ANALYSIS OF HUMAN MICROBIOME MANUFACTURING SERVICES, BY REGION, 2024
- 5.6 KEY CONFERENCES & EVENTS, 2025-2026
-
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESSDISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 CASE STUDY ANALYSIS
-
6.1 KEY TECHNOLOGIESWHOLE-GENOME SEQUENCING16S RNA SEQUENCING METHODNANOPORE SEQUENCING
-
6.2 COMPLEMENTARY TECHNOLOGIESMETATRANSCRIPTOMICSMETAGENOMICSMETABOLOMICS
-
6.3 ADJACENT TECHNOLOGIESSAMPLE PREPARATIONDATA ANALYSISLIBRARY SYNTHESIS
- 6.4 TECHNOLOGY ROADMAP
- 6.5 PATENT ANALYSIS
- 6.6 FUTURE APPLICATIONS
-
6.7 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MANUFACTURING SERVICES MARKETTOP USE CASES AND MARKET POTENTIALBEST PRACTICES IN AI-ENABLED HUMAN MICROBIOME WORKFLOWSCASE STUDIES OF AI ADOPTION IN HUMAN MICROBIOME MANUFACTURING SERVICES MARKETINTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERSCLIENTS’ READINESS TO ADOPT AI-INTEGRATED MICROBIOME ANALYTICS SOLUTIONS
-
7.1 REGIONAL REGULATIONS AND COMPLIANCEREGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONSINDUSTRY STANDARDS
- 8.1 INTRODUCTION
- 8.2 DECISION-MAKING PROCESS
-
8.3 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIAKEY STAKEHOLDERS IN BUYING PROCESSBUYING CRITERIA
- 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 9.1 INTRODUCTION
- 9.2 STRAIN DEVELOPMENT & OPTIMIZATION
- 9.3 FERMENTATION & DOWNSTREAM PROCESSING
- 9.4 FORMULATION & FILL/FINISH
- 9.5 OTHER SERVICES
- 10.1 INTRODUCTION
- 10.2 INFECTIOUS DISEASES
- 10.3 GASTROINTESTINAL DISEASES
- 10.4 ENDOCRINE & METABOLIC DISORDERS
- 10.5 OTHER DISEASES
- 11.1 INTRODUCTION
- 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 11.3 ACADEMIC & RESEARCH INSTITUTES
- 11.4 OTHER END USERS
- 12.1 INTRODUCTION
-
12.2 NORTH AMERICAUSCANADA
-
12.3 EUROPEGERMANYUKFRANCEITALYSPAINREST OF EUROPE
-
12.4 ASIA PACIFICCHINAJAPANINDIASOUTH KOREAAUSTRALIAREST OF ASIA PACIFIC
-
12.5 LATIN AMERICABRAZILMEXICOREST OF LATIN AMERICA
-
12.6 MIDDLE EASTGCC COUNTRIES- KINGDOM OF SAUDI ARABIA- UAE- REST OF GCC COUNTRIESREST OF MIDDLE EAST
- 12.7 AFRICA
- 13.1 INTRODUCTION
- 13.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN
- 13.3 REVENUE ANALYSIS, 2020-2024
- 13.4 MARKET SHARE ANALYSIS, 2024
-
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024STARSEMERGING LEADERSPERVASIVE PLAYERSPARTICIPANTS- COMPANY FOOTPRINT- REGION FOOTPRINT- SERVICE FOOTPRINT- DISEASE FOOTPRINT
-
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024PROGRESSIVE COMPANIESRESPONSIVE COMPANIESDYNAMIC COMPANIESSTARTING BLOCKSCOMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024- DETAILED LIST OF KEY STARTUPS/ SMES- COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
-
13.7 COMPETITIVE SCENARIOSERVICE LAUNCHESDEALSEXPANSIONS
-
13.8 BRAND/PRODUCT COMPARISONLONZAEVONIKEUROFINS SCIENTIFIC
- 13.9 COMPANY VALUATION AND FINANCIAL METRICS
-
14.1 KEY PLAYERSLONZA- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- MNM VIEWEVONIK- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- MNM VIEWEUROFINS SCIENTIFIC- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- MNM VIEWLALLEMAND INC.- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- MNM VIEWCERBIOS-PHARMA SA- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- MNM VIEWLIST BIOLOGICAL LABS, INC.- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- RECENT DEVELOPMENTSCHARLES RIVER LABORATORIES- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- RECENT DEVELOPMENTSELISE BIOPHARMA- BUSINESS OVERVIEW- SOLUTIONS/SERVICES OFFERED- RECENT DEVELOPMENTS
-
15.1 RESEARCH DATASECONDARY DATA- Key sources of secondary data- Key objectives of secondary dataPRIMARY DATA- Breakdown of primaries- Key objectives of primary research
-
15.2 MARKET SIZE ESTIMATIONGLOBAL HUMAN MICROBIOME MANUFACTURING SERVICES MARKET SIZE ESTIMATION, 2024- MnM Repository Analysis- Secondary Analysis- Primary ResearchSEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
- 15.3 MARKET GROWTH RATE PROJECTIONS
- 15.4 DATA TRIANGULATION
- 15.5 FACTOR ANALYSIS
- 15.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
- 15.7 RISK ANALYSIS
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
- 16.3 CUSTOMIZATION OPTIONS
- 16.4 RELATED REPORTS
- 16.5 AUTHOR DETAILS
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global human microbiome manufacturing services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include World Health Organization (WHO), Human Microbiome Manufacturing Services Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate & validate the total size of the human microbiome manufacturing services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The human microbiome manufacturing services encompasses the collective genetic material of diverse microorganisms residing within the human body, known as the metagenome. This includes bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms play a crucial role in human physiology, influencing metabolic and immune functions. Found within human tissues, the microbiome is a focal point of research for medical advancements and analytical techniques. It is applied in probiotics, prebiotics, pharmaceuticals, and therapeutic systems to address conditions such as diabetes, obesity, and cancer, as well as a range of metabolic, gastrointestinal, neurological, central nervous system, and autoimmune disorders.
The study provides an in-depth analysis of the Human Microbiome Manufacturing Services market based on contemporary market trends and developments, and its potential growth from 2025 to 2031. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key Human Microbiome Manufacturing Services service providers.
Stakeholders
- Manufacturers and Distributors of Human Microbiome Manufacturing Services Products
- Pharmaceutical and Biotechnology Companies
- Market Research and Consulting Firms
- R&D Centers
- Researchers and Scientists
- Academic & Research Institutes
- Hospitals & Clinics
- Long-term Care Centers
- Specialty Care Centers
- Outpatient Care Centers
Report Objectives
- To define, describe, and forecast the human microbiome manufacturing services market based on products, disease, drugs & supplements type, drugs & supplements route of administration, end user, manufacturing services and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall human microbiome manufacturing services market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the human microbiome manufacturing services market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the human microbiome manufacturing services market
- To benchmark players within the human microbiome manufacturing services market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Human Microbiome Manufacturing Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Human Microbiome Manufacturing Services Market